Adaptive Pharmacogenomics, LLC

Massachusetts General Hospital Cancer Center researchers have discovered massive overexpression of satellite repeats -- certain DNA sequences that do not code for proteins -- in some common tumor cells, findings that may improve knowledge of tumor development and lead to a novel cancer biomarker.

The search for biomarkers for attention deficit/hyperactivity disorder.

Drug News Perspect. 2010 Sep;23(7):438-49

Authors: Wallis D

The main characteristic of attention deficit/hyperactivity disorder (ADHD) is a persistent pattern of inattention and/or hyperactivity-impulsivity which is more frequent and severe than is usually expected in individuals at a comparable level of development. ADHD is estimated to affect approximately 5.

Pharmacogenetics and schizophrenia.

Clin Lab Med. 2010 Dec;30(4):975-93

Authors: Foster A, Miller del D, Buckley P

The wide interindividual variability in clinical response and tolerability of antipsychotic medications has led investigators to postulate that these variabilities may be under genetic control.

Mark M. Rasenick, Distinguished University Professor in physiology and biophysics and psychiatry and founding director of the Neuroscience Program at the University of Illinois at Chicago College of Medicine, has been named a Fellow by the American Association for the Advancement of Science.

Election as a Fellow is an honor bestowed upon AAAS members by their peers.

Biomarker pioneer Nuclea Biotechnologies, Inc. today announced the United States Patent and Trademark Office has issued a Notice of Allowance for a patent covering kinase peptides and antibodies.   The patent is expected to issue in the first quarter of 2011.

( from http://www. rxpgnews. com ) A new study conducted by Josh LaBaer's research team in the Biodesign Institute at Arizona State University has pinpointed more than 30 breast cancer gene targets ---including several novel genes---that are involved in drug resistance to a leading chemotherapy treatment.

The results of the study may one day aid in the treatment of the one in ten U. S.

A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives.

Pharmacogenomics.

Irinotecan pharmacogenomics.

Pharmacogenomics. 2010 Jul;11(7):1003-10

Authors: Marsh S, Hoskins JM

Irinotecan is a camptothecin analog used as an anticancer drug. Severe, potentially life-threatening toxicities can occur from irinotecan treatment.

Endocannabinoid system, pharmacogenomics and response to therapy.

Pharmacogenomics. 2010 Jul;11(7):907-10

Authors: Onaivi ES

PMID: 20602608 [PubMed - indexed for MEDLINE]

Pharmacogenetics of drug hypersensitivity.

Pharmacogenomics.